fosaprepitant
Selected indexed studies
- Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial. (Br J Anaesth, 2023) [PMID:37423834]
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. (Cancer Chemother Pharmacol, 2022) [PMID:35635561]
- The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review. (Adv Clin Exp Med, 2023) [PMID:37026971]
_Worker-drafted node — pending editorial review._
Connections
fosaprepitant is a side effect of
Sources
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. (2020) pubmed
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. (2022) pubmed
- Aprepitant and fosaprepitant drug interactions: a systematic review. (2017) pubmed
- Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial. (2023) pubmed
- The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review. (2023) pubmed
- Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy. (2016) pubmed
- Fosaprepitant as combination therapy to prevent chemotherapy-induced vomiting in children: a meta-analysis. (2025) pubmed
- Fosaprepitant Dimeglumine Alleviates Dengue Virus Infection and Virus-Induced Inflammatory Responses. (2025) pubmed
- Pharmacokinetic evaluation of fosaprepitant dimeglumine. (2010) pubmed
- Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. (2007) pubmed